Innovation Series: What a noninvasive eye drop approach may mean for the future of keratoconus
Ehsan Sadri, MD, FACS, of Visionary Eye Institute in Newport Beach, California, sat down with Professor Emeritus Colin R. Green, PhD, DSc, University of Auckland, in Auckland, New Zealand, to learn more about a novel therapy in development for the treatment of keratoconus and other corneal ectasias.
Ehsan Sadri, MD, FACS, of Visionary Eye Institute in Newport Beach, California, sat down with Professor Emeritus Colin R. Green, PhD, DSc, Department of Ophthalmology, Faculty of Medical and Health Sciences, University of Auckland, in Auckland, New Zealand, to learn more about a novel therapy in development for the treatment of keratoconus and other corneal ectasias.
Green outlines the status of the research, involving a unique combination of transforming growth factor beta-3 and dexamethasone, and the setup for a proof-of-concept study (via TheiaNova, a spin-out early-stage company of the University of Auckland).
Green also offers career advice for vision scientists and entrepreneurs, advising that making the transition from basic research to research translation is challenging and that having an application in mind is crucial. He emphasizes the importance of persevering through the highs and lows of research and development, highlighting the long-term benefits and sense of achievement.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Related Articles
- Lions World Vision Institute expands OptiGraft CAIRS service
September 17th 2025
- EyeCon 2025: Sun, sea, and a shared vision for the future of eye care
September 17th 2025
- Achieving Functional Vision in Patients Seeking Freedom From Glasses
September 15th 2025
- Expanding the Depth of Focus With IC-8 Apthera IOL
September 15th 2025